Daclizumab

CLINICAL USE

Humanised murine/human monoclonal anti-CD25 antibody:Prophylaxis of acute allograft rejection, in combination with maintenance immunosuppressants

DOSE IN NORMAL RENAL FUNCTION

1 mg/kg within 24 hours of transplantation, then 1 mg/kg every 14 days for 5 doses. See ‘Other Information’

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :144 000

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data

%Excreted unchanged in urine &nbsp &nbsp : No data

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :5.3 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :270–919/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsNone known

ADMINISTRATION

Reconstition

–

Route

IV infusion

Rate of Administration

Over 15 minutes

Comments

Add required dose to 50 mL of sodium chloride 0.9%Stable for 24 hours at 2–8°C if prepared aseptically

OTHER INFORMATION

An alternative dosing regimen that may be used is 2 mg/kg every 14 days for 2 doses

Tags: post-by-auto-php